1996
DOI: 10.1016/0300-483x(95)03279-o
|View full text |Cite
|
Sign up to set email alerts
|

Further evaluation of the local lymph node assay in the final phase of an international collaborative trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
80
0

Year Published

1999
1999
2010
2010

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 181 publications
(85 citation statements)
references
References 30 publications
5
80
0
Order By: Relevance
“…A good example is DNCB, a chemical that has been extensively tested by multiple methods. Even here, the comparisons are complicated by the fact that different endpoints are being evaluated; local lymph node cell proliferation (LLNA) in the mouse (39), erythema in the guinea pig (40), and skin fold thickness changes in man (33). In spite of these differences, the comparison of the dose per unit area resulting in approximately 1 / 4 to 1 / 2 maximal responses for each method were remarkably similar; 25 (mg/cm 2 ) in the mouse (39) and guinea pig (40) and 16.4 (mg/cm 2 ) in man (33).…”
Section: Comparison Of Exposures In Animal Andmentioning
confidence: 99%
“…A good example is DNCB, a chemical that has been extensively tested by multiple methods. Even here, the comparisons are complicated by the fact that different endpoints are being evaluated; local lymph node cell proliferation (LLNA) in the mouse (39), erythema in the guinea pig (40), and skin fold thickness changes in man (33). In spite of these differences, the comparison of the dose per unit area resulting in approximately 1 / 4 to 1 / 2 maximal responses for each method were remarkably similar; 25 (mg/cm 2 ) in the mouse (39) and guinea pig (40) and 16.4 (mg/cm 2 ) in man (33).…”
Section: Comparison Of Exposures In Animal Andmentioning
confidence: 99%
“…Thus, a potential limitation of the ex vivo LLNA, as with the standard assay, is the possibility of false-positive findings due to irritation or, in the case of citral, over-estimating the sensitization potential. Hexylcinnamic aldehyde is a weak sensitizer in humans (Basketter and Kimber, 2001); however, this compound is a weak to moderate sensitizer in the LLNA (Tables 5 and 6; Loveless et al, 1996;Basketter et al, 1999). This difference in potency classification also may be attributed to an over-estimation due to the irritancy properties of this compound.…”
Section: Discussionmentioning
confidence: 99%
“…Mice (4/group) were treated by topical application with 25 µl of test substance in acetone to the dorsum of both ears on Days 1-3 using a single channel pipetter. Basketter et al, 1999;Ryan et al, 2000; The concentrations tested for each compound listed in Table 1 were based on published reports (Basketter et al, 1994Loveless et al, 1996;Ryan et al, 2000). Control animals were treated with vehicle (acetone) alone.…”
Section: Ex Vivo Llnamentioning
confidence: 99%
“…Although we aimed at having responses in the short-term experiments of SI = 2, this was not always achieved. Variations in lymph node responses to sensitizers have previously been reported (Loveless et al, 1996;Dearman et al, 1998;De Jong et al, 2002a). Several factors may be responsible for variability in the performance of the assay including the animals used and minimal variations in the actual dose received by the animals.…”
Section: Exposure To Chemicalmentioning
confidence: 95%
“…The LLNA has the advantage over the guinea pig assays in that objective quantitative results are obtained by measurement of tritiated-thymidine incorporation in proliferating cells. The LLNA has been evaluated extensively and compared to the GPMT and human patch testing (Basketter and Scholes, 1992;Kimber, et al, 1995;Loveless et al, 1996;Gerberick et al, 2000).…”
Section: Introductionmentioning
confidence: 99%